The DOI matches its Crossref record; 88 of the 90 references it cites were found in a registry or an index.
Active and Passive Immunotherapy for Neurodegenerative Disorders
Open accessAbstract
Immunotherapeutic strategies to combat neurodegenerative disorders have galvanized the scientific community since the first dramatic successes in mouse models recreating aspects of Alzheimer disease (AD) were reported. However, initial human trials of active amyloid-beta (Abeta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. Nonetheless, some encouraging preliminary data were obtained, and rapid progress has been made toward developing alternative, possibly safer active and passive immunotherapeutic approaches for several neurodegenerative conditions. Many of these are currently in human trials for AD. Despite these advances, our understanding of the essential mechanisms underlying the effects seen in preclinical models and human subjects is still incomplete. Antibody-induced phagocytosis of pathological protein deposits, direct antibody-mediated disruption of aggregates, neutralization of toxic soluble proteins, a shift in equilibrium toward efflux of specific proteins from the brain, cell-mediated immune responses, and other mechanisms may all play roles depending on the specific immunotherapeutic scenario.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Certain types of active and passive immunization have resulted in significant side effects such as brain edema and hemorrhages (Brody and Holtzman, 2008).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Brody and Holtzman, 2008
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previously, a variety of different anti-Aβ antibodies have been shown to inhibit Aβ accumulation in mouse models of Aβ amyloidosis, and they are considered promising disease-modifying therapies (Brody and Holtzman, 2008; Golde et al., 2009).”
From Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) · cites this paper as Brody and Holtzman, 2008
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have demonstrated that anti-Aβ antibodies can effectively decrease amyloid accumulation when they are given preventatively, but they are less effective in a treatment mode (Brody and Holtzman, 2008; Golde et al., 2009).”
From Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) · cites this paper as Brody and Holtzman, 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedDevelopments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Cited by
Sorted by citations
Items 201–250 of 250
Learning impairment by minimal cortical injury in a mouse model of Alzheimer׳s disease
Zou, J., Wang, M., Uchiumi, O., Shui, Y., Ishigaki, Y., Liu, X., Tajima, N., Akai, T., Iizuka, H., & Kato, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.017 · Cited by 5
Virus-Like Particles as Efficient Delivery Platform to Induce a Potent Immune Response
Rebeaud, F., & Bachmann, M. F. (2012) · Springer eBooks · doi:10.1007/978-94-007-4543-8_5 · Cited by 5
Current Strategies of Therapy in Alzheimer`s Disease
Martocchia, A., & Falaschi, P. (2008) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800801010019 · Cited by 5
Imaging in Neurology Research II: PET Imaging of CNS Disorders
Henriksen, G., & Drzezga, A. E. (2010) · Springer eBooks · doi:10.1007/978-3-642-12945-2_33 · Cited by 5
Processo Inflamatório e Neuroimunomodulação na Doença de Alzheimer
Rocha, N. P., Martins, L. D. C. A., Teixeira, A. L., & Reis, H. J. (2001) · Revista Neurociências · doi:10.34024/rnc.2011.v19.8385 · Cited by 24
A review on current theories and potential therapies for prion diseases
Udayakumar, S., Girigoswami, A., & Girigoswami, K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10754-2 · Cited by 4
Mondal, A. C., & Sushma (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211228100955 · Cited by 4
Virus-like Particles-based Vaccine to Combat Neurodegenerative Diseases
Lim, L. W. C., Jy, L., Chen, C. H., Voon, K., Koh, R. Y., & Chye, S. M. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010331763241002122854 · Cited by 3
Lannfelt, L., Pettersson, F. E., & Nilsson, L. N. G. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00347.x · Cited by 3
Santiago-Lopez, A. J., Hovell, C. M., Lee, H., & Kim, Y. (2015) · Biosystems & biorobotics · doi:10.1007/978-3-319-21813-7_13 · Cited by 3
Sialic Acid Conjugated Chitosan for the Attenuation of Amyloid-beta Toxicity
Dhavale, D. D. (2009) · Louisiana State University · doi:10.31390/gradschool_theses.3810 · Cited by 3
The Progress of Active Immunotherapy for Parkinson’s Disease
Busot, D., Yang, H., Sawmiller, D. R., & Cao, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052194 · Cited by 2
Auf dem Weg zu einer Impfung gegen Alzheimer?
Dodel, R. C. (2013) · Drug Research · doi:10.1055/s-0033-1346715 · Cited by 2
The Immunopathy of Alzheimer’s Disease: Innate or Adaptive?
Weaver, D. F. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230517103312 · Cited by 2
Targeting Assembly and Disassembly of Protein Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00006-0 · Cited by 2
Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_8 · Cited by 2
Bayer, T. A., & Wirths, O. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2496-0 · Cited by 2
Fernández, T. (2014) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.32262 · Cited by 2
Toxicity Study in Alzheimer's Disease Cell Model
Suryadi, V. R. (2014) · Cited by 2
Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer’s disease
He, C., Shen, Y., Zhang, M., & Zhou, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1603553 · Cited by 1
Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations
Varte, V., Ralte, L., & Kumar, N. S. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00203-y · Cited by 7
O’Donovan, J. (2011) · Reviews in Clinical Gerontology · doi:10.1017/s0959259811000141 · Cited by 1
Lanning, J. D., & Meredith, S. C. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_14 · Cited by 1
Pinzer, B., Cacquevel, M., Modregger, P., Thuering, T., & Stampanoni, M. (2013) · Journal of Instrumentation · doi:10.1088/1748-0221/8/05/c05005 · Cited by 1
Feng, G., Zheng, C., & Hui, J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.049 · Cited by 1
Innovative Therapie der Alzheimer-Demenz
Dodel, R. C., & Bacher, M. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2499-x · Cited by 1
Efficacy of Multifunctionalized Saccharide Constructs for the Attenuation of Amyloid-beta Toxicity
Dhavale, D. D. (2012) · Louisiana State University · doi:10.31390/gradschool_dissertations.2446 · Cited by 1
Tachibana, T., & Kuwabara, T. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.01.006 · Cited by 1
Alzheimer-Demenz : Molekulare Pathologie, Tiermodelle und Therapiestrategien
Bayer, T. A., & Wirths, O. (2008) · Der Nervenarzt · Cited by 1
Verlaufsmodifizierende Therapien der Alzheimer-Demenz
Heneka, M. T. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3000-1
Mechanisms of Brain Region-Specific Amyloid-beta Deposition
Bero, A. W. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7cj8bh2
Immunosignature of Alzheimer's Disease
Jimenez, L. R. (2011)
Untersuchungen zu synaptischen Proteinen in einem Tiermodell für die Alzheimer-Krankheit
Wente, S. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1037
Development of Immunization Approaches to Amyotrophic Lateral Sclerosis
Gros‐Louis, F., Gowing, G., & Julien, J. (2009) · Future Neurology · doi:10.2217/fnl.09.21
Antibody Based Therapeutics for Alzheimer's Disease
Boddapati, S. P. (2011)
Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease
Yang, S., Kim, J., & Kim, Y. S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_22
Price, D. L., Savonenko, A. V., Li, T., & Wong, P. C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.009
Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms
Yanamandra, K., Diamond, M. I., & Holtzman, D. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_9
Self-citationAlzheimer’s Disease and the Sleep–Wake Cycle
Bero, A. W., & Tsai, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00010-3
Selektion und Charakterisierung von Bindeproteinen für amyloidogene Peptide und Proteine
Hoyer, W. (2021) · De Gruyter eBooks · doi:10.1515/9783110720037-060
Engineering antibody therapeutics and cell culture models for neurodegenerative diseases
McHugh, K. P. (2016) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/9ar9-m703
Assembly and Disassembly of Protein Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800186-8.00006-7
Deciphering New Drug Targets in Alzheimer’s Disease
Verma, N., Thapa, K., Kanojia, N., Kaur, G., Sood, P., & Dua, K. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_1
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936
del Valle, M. L., & Arienzo, D. (2026) · Ibrain · doi:10.1002/ibra.70016
Concepts, types, and treatment strategies for neurodegenerative disorders
Rana, R., Jaiswal, S., Sethi, M., Tripathi, S., Mishra, K., Gupta, P., & Chourasia, M. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00003-9
Pretargeted imaging beyond the blood–brain barrier: From concept to reality
Wuensche, T. E., Stotz, S., Battisti, U. M., & Herth, M. M. (2026) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2026.109653
Nucleic acid drug therapies for CNS diseases: Present status and future perspectives
Chen, Y., Kuriakose, D., & Xiao, Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44631-3.00006-8
Targeting protein aggregate co-pathologies in neurodegeneration: a viable therapeutic strategy?
Buck, S. A., Madhavan, S. S., & Sanders, L. H. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00047-8
Metadata
- Authors
- Brody, D. L., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Venue
- Annual Review of Neuroscience
- Publisher
- Annual Reviews
- Published
- 2008-07-01
- Volume
- 31
- Issue
- 1
- Pages
- 175-193
- ISSN
- 0147-006X (ISSN-L)
- 1545-4126
- PMC
- PMC2561172
- OpenAlex
- W2100298346
- Cited by
- 250
- References
- 90
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 5 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 6 · 2016: 10 · 2015: 13 · 2014: 17 · 2013: 19 · 2012: 22
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annual Review of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5k08ns049237-05)
- National Institute on Aging (AG20222, R01AG020222, R01AG013956, R37AG013956, AG13956)
- National Institute of Neurological Disorders and Stroke (NS049237, K08-NS049237)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- neurodegenerative diseases, Alzheimer's disease, active immunotherapy, passive immunotherapy, meningoencephalitis, antibody-mediated phagocytosis, cell-mediated immunity, immunotherapy safety
- MeSH terms
- Animals, Antibodies, Humans, Immunity, Immunization, Passive, Nerve Tissue Proteins, Vaccination, Amyloid beta-Peptides, Immunotherapy, Active, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
